Geographic atrophy

Two Studies Give Positive Marks to Pegcetacoplan Therapy for GA

Real-world results show that the drug reduced annual growth rate by about 34%. A clinical trial extension also reported a similar level of efficacy.
05/07/2024

Similarities and Differences Between Pachychoroid GA and Conventional GA Identified

Understanding these features may help disease diagnosis in Asian populations. Patients with the former subtype were significantly younger, predominantly male and had a slower progression rate.
04/12/2024

Study Finds Imaging Biomarkers Associated with GA Growth Rate

Progression is positively associated with non-exudative subretinal fluid and hyperreflective material as well as iRORA. It’s negatively associated with retinal pseudocysts and subfoveal choroid thickness.
04/01/2024

Pachydrusen in AMD Eyes Raises Risk of MNV but Not GA

This is especially the case when macular pigmentary changes are also present, study finds.
03/20/2024

Investigative GA Drug Fares Poorly in Phase II Trial

After 24 months of treatment with oral minocycline, participants showed no significant decrease in lesion enlargement rate. Mild and moderate AEs were also common.
03/19/2024

Investigational Subretinal Implant Could Help Restore Vision Loss from GA

Device seeks to mimic photoreceptor function and re-enable retinal neurons. Three subjects gained at least four ETDRS lines in recent tests.
03/12/2024

Thin Double Layer Sign in the Fovea on OCT Predicts GA

Structural imaging shows the presence of biomarkers associated with the development of foveal atrophy at two years.
02/14/2024

AMD Genetic Profile Predictive of Early GA Enlargement

ARMS2/HTRA1 is an important risk factor for identifying eyes likely to experience fast lesion progression.
09/19/2023

New GA Drug from Iveric Bio Approved

Clinical trials show Izervay can slow disease progression with as few as six monthly doses.
08/07/2023

Novel Microperimetry Endpoints Better at Detecting Functional Decline in GA

The metrics could lead to future clinical trials that better characterize both the natural history of the disease as well as early treatment response, the authors suggest.
06/16/2023

Upcoming Events

June 26, 2024

Patient-Centered Communications: Practical Strategies for Discussing EVO ICL
Location: Virtual
Presenters: George Waring, IV, MD, and Marc Bloomenstein, OD
Webinar: 6:00pm PT

Sponsored by STAAR Surgical

Register here

September 8, 2024

Ocular Surface Symposium
Location: Renaissance Chicago Downtown Hotel
Presenter:  Paul Karpecki, OD

Register here

November 15-17, 2024

New Technologies & Treatments in Eye Care and Intrepid Eye Society's Fall Conference
Location: Grand Hyatt Nashville
Co-Chairs: Paul Karpecki, OD,  and Selina McGee, OD

Register here